Organophosphate Poisoning and Management, an Update. by Nhachi, C.F.B.
Vol. 47, No. 5 CONTENTS
ORIGINAL ARTICLES
HIV-l seroconversion incidence following 
pregnancy and delivery among women 
seronegative at recruitment in Harare, Zimbabwe
MT Mbizvo, J Kasule, K Mahomed,
K Nathoo............................................................
Prevalence of causative organisms in corneal ulcers 
seen at Sekuru Kaguvi Eye Unit, Harare, Zimbabwe
MG Wani, NA Mkangamwi,
S Guramatunhu..................................................
Maternal outcome in eclampsia at Harare 
Maternity Hospital................................................ F Majoko, C Mujaji ...........................................
Caesarean section rate as a process indicator of safe 
motherhood programmes: the case of Midlands 
Province ................................................................ A Zezai, L Apers, C Zishiri..............................
CONTINUED HEALTH EDUCATION
Organophosphate poisoning and management, 
an update............................................................... CFB Nhachi.......................................................
LETTERS TO THE EDITOR
Susceptibility of Klebsiella species to quinolones 
and cephalosporins................................................ C Si mango, J Licas............................................
RETRACTION
Retraction of articles: K Bhagat et a l ................... Central African Journal of Medicine................
NOTES AND NEWS
Instructions to Authors......................................... Central African Journal of Medicine................
CONTINUED HEALTH EDUCATION __________________________________
Organophosphate poisoning and management, an update
CFB NHACHI
Abstract
Organophosphate poisoning is characterised for the most part, by acute incidents. Management is by way of 
first aid (in mild poisoning) and use of atropine with or without the oximes, (in moderate to severe poisoning). 
Of late, it has become apparent that subchronic and chronic organophosphate poisoning are a common 
manifestation. This review paper summarises this triphasic nature of organophosphate poisoning. Possible 
future diagnostic and management techniques are also discussed.
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Introduction
Poisoning from pesticides accounts for 15 % of all poisoning 
admissions cases in Zimbabwe, 10% of which are due to 
organophosphate (OP), pesticides.1 Most OP poisoning 
incidents are associated with occupational exposures (in 
the agro-chemical industry), accidental poisonings (in 
industry/factory), and suicide/parasuicides. The bulk of 
pesticides used in Zimbabwe (over 50%) are 
organophosphates, (O Ps).
Review
Organophosphate poisoning can be subdivided into three 
phases, i.e. acute poisoning, which is characterised by 
inhibition of nerve tissue acetylcholinesterase and 
accumulation of free unbound acetylcholine at the nerve 
endings of all cholinergic nerves; an intermediate syndrome, 
which consists of neurological signs, 24 to 96 hours after 
acute exposure; and an Organophosphate Induced Delayed 
Peripheral Neuropathy, (OPIDPN), which occurs seven to 
14 days after exposure. Currently, there are a number of 
clinical research studies, aimed at enhancing management 
and definitive diagnosis of organophosphate poisoning. 
Acute Poisoning.
Acute OP poisoning syndrome is characterised by 
inhibition of nerve tissue acetylcholinesterase and 
accumulation of free unbound acetylcholine at the nerve 
endings of all cholinergic nerves. The result is a continual 
stimulation of electrical activity. The signs and symptoms 
of acute OP poisoning can be subdivided into three 
categories, according to the severity of the.poisoning.
Mild Poisoning: Inmild poisoning, the victim can walk 
but may experience fatigue, headaches, dizziness, nausea 
and vomiting, numbness, sweating and salivation, tightness 
in the chest, abdominal cramps and diarrhoea. If the serum 
cholinesterase levels are inhibited by 20 to 50% of normal 
levels, it is recommended that atropine be administered 
(sulphate) i.v. ori.m. 1 to2m g every lOto 15 minutes until 
signs of atropinization appear, i.e. dry mouth, dilated or 
normal pupils and pulse rate of between 75 to 85 per 
minute. The atropine dose should be repeated to maintain 
atropinization. If less than 24 hours have elapsed since the 
incident, pralidoxime, i.v. or i.m. may be given in addition. 
Under these conditions, the prognosis is usually good.2-3
Moderate Poisoning: In moderate poisoning the victim 
may have difficulty in walking or might not be able to walk 
at all. The serum cholinesterase activity is inhibited by 
over 80%. It is recommended that atropine be administered 
1 to 2 mg every 10 to 15 minutes until atropinization. 
Atropinization should be maintained. If it is less than 24 
hours since the exposure, pralidoxime,lg i.v. or i.m. may 
be given and repeated every four to six hours. It is important 
to note that while oximes may be beneficial, Pralidoxime 
is associated with less side effects than Obidoxime, which 
in high doses is associated with hepatotoxicity. The rationale 
of using oximes is based on the fact that, if administered,
within 24 hours, oximes, help to reverse the OP + 
cholinesterase interaction compound and thereby make 
available more enzyme.
By the point of atropinezation, some patients may 
experience and exhibit delirium and hallucinations, which 
is associated with atropine toxicity on the central nervous 
system.
Severe Poisoning: In severe poisoning, the patient may 
be unconscious and showing signs of difficulty in breathing. 
Other signs and symptoms are pupillary reflex to light, 
flaccid paralysis and prominent miosis. Because of the 
difficulty in breathing, the victim may be cyanotic. The 
serum cholinesterase activity levels are usually at least 
95% inhibited. Treatment should consist of a high dose of 
atropine, 2mg i.v. every 10 minutes until sweating and/ or 
salivation disappear and /Or mydriasis or normal pupil 
reaction develops. If not treated promptly, severe OP 
poisoning is fatal. Mechanical ventilation is needed in 
moderate to severe poisoning. Diazepam lOmg i.v., may 
be needed for convulsions and the dose may be repeated. 
Atropine eye drops may relieve headaches.8
Both plasma cholinesterase (sometimes referred to as 
pseudocholinesterase) and erythrocyte acetylcholinesterase 
are used for diagnosis of the magnitude of OP poisoning 
and monitoring of OP exposures. At the same intensity of 
exposure, plasma cholinesterase is significantly more 
inhibited than erythrocyte cholinesterase. Plasma 
cholinesterase recovery to normal (pre-exposure) levels 
takes 5 0 days and that of erythrocyte cholinesterase recovers 
after 82 days (interestingly a time frame that is shorter than 
the life-span of erythrocytes). As a result, the recommended 
minimum period without exposure, to establish pre­
exposure base-line levels is 60 days.9However, it must be 
pointed out that most diagnoses of acute organophosphate 
poisoning are made clinically and this is reliable. 
Intermediate Poisoning.
The intermediate syndrome (IMS) of organophosphate 
poisoning consists of neurological signs 24 to 96 hours 
after acute toxic exposure. These signs are characterised 
by muscle weakness, (muscles innervated by the cranial 
nerves i.e. the neck, flexors and respiratory muscles) and 
the limbs. This may be accompanied by respiratory 
depression and distress. Urgent ventilation of the victim 
may. be required. Some of the organophosphates that are 
associated with the intermediate syndrome are fenithion, 
dimethoate, monocrotophos and methamidophos. There is 
no known antidote for this syndrome.
Chronic Poisoning.
Some organophosphates induce delayed neurotoxicity, 
referred to as Organophosphate Induced Delayed Peripheral 
Neuropathy, (OPIDPN).10
OPIDPN is characterised pathologically, by symmetrical 
sensory motor axonopathy which tends to be severe in long 
axons. The histological lesion is a “dying back” of axons 
as opposed to demyelination. Clinically the syndrome is 
associated with flaccid paralysis of the lower limbs and in 
severe cases the upper limbs too. There is muscle weakness
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in arms and legs leading to clumsy shuffling and high 
stepping gait. This may be replaced by spasticity and 
abnormal reflexes, perhaps a pointer to damage to the 
pyramidal tracts.11
OPIDPN occurs seven to 14 days after exposure. There 
is no known treatment for itvRecovery in victims is limited 
to the arms and legs but foot' drops, spasticity and 
hyperactive reflexes may become irreversible. It is 
suggested that this is a result of spinal cord injury.
The Future.
Some of the OP1 which are associated with OPIDPN 
include, EPN (on-ethyl o-p-nitrophenyl 
phenylphosphonate), cyanofenphos and trichloronat. These 
OPs inhibit a non specific carboxylesterase called the 
neuropathic target estarase (NTE). A 70 to.80% inhibition 
of NTE results in induction of OPIDPN. The OPs with 
potent anticholinesterase activity have no OPIDPN activity 
at all.
Current clinical research in organophosphate poisoning 
is aimed at optimising both treatment and definitive 
diagnosis. Promising results have come out of research 
using erythrocytes as carrier models of phosphodiesterase 
to antagonize the toxic effects of OPs. Erythrocytes, packed 
with a recombinant phosphodiesterase have been shown to 
provide protection against toxicity to paraoxon, an OP. 
Phosphotriesterase hydrolyses paraoxon to a non toxic 
metabolite,12 and this would augument the use of atropine.
As far as definitive diagnosis is concerned, the recent 
development of a sensitive ELISA (enzyme-linked 
immunosorbent assay) for the measurement of protein 
mass of serum cholinesterase (CHE) provides exciting 
promises. It is envisaged (and has been demonstrated in 
clinical research on OP poisoned patients) that protein 
mass determination of serum CHE provides valuable 
' information concerning the target value of serum CHE 
activity for treatment of OP poisoning patients. The 
technique is also valuable for investigating the specific 
activity of generic variants of serum CHE:13
Both the intermediate and chronic syndromes seem to be 
related to the chemical nature of the compound and may 
also be a result of ineffective management of the acute 
syndrome.
Conclusion
In conclusion, it has been established that OP poisoning 
has three phases, as outlined above. Recent developments 
have pointed at improved development of diagnostic 
methods and management of diagnostic and management 
techniques.
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